Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86


NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines.

Huergo-Zapico L, Parodi M, Cantoni C, Lavarello C, Fernández-Martínez JL, Petretto A, DeAndrés-Galiana EJ, Balsamo M, López-Soto A, Pietra G, Bugatti M, Munari E, Marconi M, Mingari MC, Vermi W, Moretta L, González S, Vitale M.

Cancer Res. 2018 Jul 15;78(14):3913-3925. doi: 10.1158/0008-5472.CAN-17-1891. Epub 2018 May 11.


[Effect of Epithelial-to-mesenchymal Transition on Biological Activity of NK Cells in Esophageal Squamous Cell Carcinoma].

Gao FX, Wu J, Ren DL.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2019 Jan;50(1):40-47. Chinese.


Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells.

Woods K, Pasam A, Jayachandran A, Andrews MC, Cebon J.

Front Oncol. 2014 Dec 17;4:367. doi: 10.3389/fonc.2014.00367. eCollection 2014. Review.


Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor.

López-Soto A, Huergo-Zapico L, Galván JA, Rodrigo L, de Herreros AG, Astudillo A, Gonzalez S.

J Immunol. 2013 Apr 15;190(8):4408-19. doi: 10.4049/jimmunol.1202950. Epub 2013 Mar 18.


Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines.

Noguchi K, Dalton AC, Howley BV, McCall BJ, Yoshida A, Diehl JA, Howe PH.

PLoS One. 2017 May 17;12(5):e0177830. doi: 10.1371/journal.pone.0177830. eCollection 2017.


Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells.

Markel G, Seidman R, Besser MJ, Zabari N, Ortenberg R, Shapira R, Treves AJ, Loewenthal R, Orenstein A, Nagler A, Schachter J.

PLoS One. 2009;4(5):e5597. doi: 10.1371/journal.pone.0005597. Epub 2009 May 19.


Proteomic analysis of ovarian cancer cells during epithelial-mesenchymal transition (EMT) induced by epidermal growth factor (EGF) reveals mechanisms of cell cycle control.

Grassi ML, Palma CS, Thomé CH, Lanfredi GP, Poersch A, Faça VM.

J Proteomics. 2017 Jan 16;151:2-11. doi: 10.1016/j.jprot.2016.06.009. Epub 2016 Jul 6.


NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?

Cantoni C, Huergo-Zapico L, Parodi M, Pedrazzi M, Mingari MC, Moretta A, Sparatore B, Gonzalez S, Olive D, Bottino C, Castriconi R, Vitale M.

J Immunol Res. 2016;2016:4684268. doi: 10.1155/2016/4684268. Epub 2016 May 12. Review.


Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor.

Balsamo M, Vermi W, Parodi M, Pietra G, Manzini C, Queirolo P, Lonardi S, Augugliaro R, Moretta A, Facchetti F, Moretta L, Mingari MC, Vitale M.

Eur J Immunol. 2012 Jul;42(7):1833-42. doi: 10.1002/eji.201142179. Epub 2012 May 25.


Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity.

Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, Balsamo M, Conte R, Benelli R, Minghelli S, Solari N, Gualco M, Queirolo P, Moretta L, Mingari MC.

Cancer Res. 2012 Mar 15;72(6):1407-15. doi: 10.1158/0008-5472.CAN-11-2544. Epub 2012 Jan 18.


NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor.

Vitale M, Della Chiesa M, Carlomagno S, Pende D, Aricò M, Moretta L, Moretta A.

Blood. 2005 Jul 15;106(2):566-71. Epub 2005 Mar 22.


PI3K signalling is required for a TGFβ-induced epithelial-mesenchymal-like transition (EMT-like) in human melanoma cells.

Schlegel NC, von Planta A, Widmer DS, Dummer R, Christofori G.

Exp Dermatol. 2015 Jan;24(1):22-8. doi: 10.1111/exd.12580. Epub 2014 Nov 18.


Estradiol promotes epithelial-to-mesenchymal transition in human benign prostatic epithelial cells.

Shi X, Peng Y, Du X, Liu H, Klocker H, Lin Q, Shi J, Zhang J.

Prostate. 2017 Oct;77(14):1424-1437. doi: 10.1002/pros.23404. Epub 2017 Aug 29.


Mesenchymal to amoeboid transition is associated with stem-like features of melanoma cells.

Taddei ML, Giannoni E, Morandi A, Ippolito L, Ramazzotti M, Callari M, Gandellini P, Chiarugi P.

Cell Commun Signal. 2014 Apr 1;12:24. doi: 10.1186/1478-811X-12-24.


The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.

Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari A, Lacour JP, Ballotti R, Deckert M, Tartare-Deckert S.

PLoS One. 2012;7(7):e40378. doi: 10.1371/journal.pone.0040378. Epub 2012 Jul 20.


Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo.

Ziegler E, Hansen MT, Haase M, Emons G, Gründker C.

Breast Cancer Res Treat. 2014 Nov;148(2):269-77. doi: 10.1007/s10549-014-3159-4. Epub 2014 Oct 8. Erratum in: Breast Cancer Res Treat. 2016 Feb;156(1):209-10.


Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells.

Ronca R, Di Salle E, Giacomini A, Leali D, Alessi P, Coltrini D, Ravelli C, Matarazzo S, Ribatti D, Vermi W, Presta M.

Mol Cancer Ther. 2013 Dec;12(12):2760-71. doi: 10.1158/1535-7163.MCT-13-0487. Epub 2013 Oct 15.


Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment.

Parodi M, Pedrazzi M, Cantoni C, Averna M, Patrone M, Cavaletto M, Spertino S, Pende D, Balsamo M, Pietra G, Sivori S, Carlomagno S, Mingari MC, Moretta L, Sparatore B, Vitale M.

Oncoimmunology. 2015 May 29;4(12):e1052353. eCollection 2015 Dec.


Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction.

Peng YP, Zhang JJ, Liang WB, Tu M, Lu ZP, Wei JS, Jiang KR, Gao WT, Wu JL, Xu ZK, Miao Y, Zhu Y.

BMC Cancer. 2014 Oct 2;14:738. doi: 10.1186/1471-2407-14-738.


Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity.

Pasero C, Gravis G, Guerin M, Granjeaud S, Thomassin-Piana J, Rocchi P, Paciencia-Gros M, Poizat F, Bentobji M, Azario-Cheillan F, Walz J, Salem N, Brunelle S, Moretta A, Olive D.

Cancer Res. 2016 Apr 15;76(8):2153-65. doi: 10.1158/0008-5472.CAN-15-1965. Epub 2016 Apr 5.

Supplemental Content

Support Center